Advanced Clinical Molecular Diagnostics: Detection of Inherited Diseases

Advanced Clinical Molecular Diagnostics: Detection of Inherited Diseases

  • Module: 2
  • Lecture: 1
  • Instructor: Professor Labiner
  • Course Code: MLSC 4053

Learning Objectives

  • Chromosomal Abnormalities: Describe chromosomal structural abnormalities and recognize large-scale abnormalities affecting chromosome number or structure.
  • Detection Methods: Explain how methodologies such as karyotyping and Fluorescence In Situ Hybridization (FISH) are utilized by molecular laboratories to detect mutations ranging from large scale to fine detail.
  • Single-Gene Mutations: Describe single-gene mutations and their phenotypic patterns across structural proteins, receptor proteins, enzymes, and cell growth factors.
  • Molecular Strategies: Compare and contrast testing strategies for single-point mutations versus nucleotide repeat (triplet repeat) diseases.
  • Inheritance Patterns: Describe Mendelian patterns of inheritance as illustrated via family pedigree diagrams.
  • Case Study (Cystic Fibrosis): Review molecular diagnostic methods for genes with multiple mutation possibilities, specifically the CFTR gene.

Models of Disease Etiology

  • Genetic: Categorized as inherited diseases.
  • Environmental: Categorized as somatic mutations or influences.
  • Multifactorial: A combination of polygenic factors and somatic/environmental influences.
  • Chromosomal Abnormalities: Large-scale changes in chromosome number or structural integrity.

Family History and Pedigree Diagrams

  • Symbols in Pedigree Diagrams:     * Square (□\Box): Represents a male.     * Circle (◯\bigcirc): Represents a female.     * Affected Male/Female: Indicated by a filled/shaded symbol.     * Deceased Person: Indicated by a diagonal slash through the symbol.
  • Transmission Patterns revealed by Pedigrees:     * Autosomal Dominant (AD): Typically appears in every generation.     * Autosomal Recessive (AR): Often skips generations; affected individuals usually have carrier parents.     * Sex-linked (X-linked recessive): Pattern showing inheritance through the X chromosome, often affecting males more frequently.

Mendelian and Molecular Transmission Patterns

  • Single-Gene Disorders: Diseases caused by a single genetic mutation. These follow standard transmission patterns: Autosomal Recessive, Autosomal Dominant, and Sex-linked.
  • Mendelian Inheritance Assumption: Prediction of transmission patterns relies on the assumption that the mutant allele follows Mendelian rules.
  • Functional Characterization of Mutations:     * Gain of Function: Mutations that result in a new or enhanced function; these typically display a dominant phenotype.     * Loss of Function: Mutations that result in reduced or eliminated function; these typically display a recessive phenotype.     * Dominant Negative Patterns: Observed when a loss of function mutation occurs in a protein that forms part of a multimeric complex, interfering with the function of the wild-type subunits.

Loss of Heterozygosity (LOH)

  • Definition: LOH occurs when a somatic mutation or deletion affects the normal allele in a heterozygous individual, leaving only the mutant allele.
  • Phenotypic Impact: Autosomal recessive mutations may result in an abnormal phenotype in a hemizygous state (mutant/deletion\text{mutant/deletion}) if the normal allele is lost.
  • Mechanism: LOH often results from somatic events such as deletions of the normal chromosomal segment.

Molecular Detection of Single Gene Disorders: Case Studies

Hemochromatosis Type I

  • Pathophysiology: A condition characterized by the over-absorption of iron from dietary sources.
  • Genetics: Caused by mutations in the HFE gene, which encodes a membrane iron transporter. The HFE protein product interacts with β2\beta_{2}-microglobulin at the cell membrane.
  • Major Mutations:     * C282YC282Y: The primary mutation associated with the disease.     * H63DH63D and S65CS65C: Other common mutations.
  • Detection Method (PCR-RFLP for C282YC282Y):     * The G→AG \rightarrow A mutation in Exon 4 creates a new recognition site for the restriction enzyme RsaIRsaI.     * Digestion Fragments: Wild-type (+/++/+) yields specific bands, while the mutation (m/mm/m) creates additional fragments.     * Fragment sizes documented: 240 bp240\,bp, 140 bp140\,bp, 110 bp110\,bp, and 30 bp30\,bp.
  • Clinical Presentation: Visible on a liver biopsy using Hemosiderin stains, categorized by levels: Normal, Slt (Slight), Mod (Moderate), and Mkd (Marked).

Factor V Leiden (R506Q)

  • Pathophysiology: A thrombophilic state (hypercoagulable phenotype) caused by a mutation in the gene for coagulation factor V (FVL).
  • Molecular Cause: A G→AG \rightarrow A transition at position 506 (R506Q).
  • Detection Methods:     * PCR-RFLP: In Exon 10, the mutation destroys an existing MnlIMnlI restriction site. Expected band sizes include 153 bp153\,bp, 116 bp116\,bp, 67 bp67\,bp, and 37 bp37\,bp.     * SSP-PCR (Sequence-Specific Primer PCR): Uses primers specific to the mutation. The longer primer ends on the mutated base (A), producing a larger amplicon of 148 bp148\,bp for the mutation versus 123 bp123\,bp for the normal allele.     * INVADER Assay: A flap-probe-based assay. A mutation-specific probe (Mut probe) forms a complex that allows cleavage only if the mutation is present. Fluorescence in the plate well indicates a positive result.
  • Thrombosis Risk Factors (Multipliers (×\times)):     * Oral Contraceptive (OC) usage: 4×4\times     * FV Leiden, Heterozygous: 2−3×2-3\times     * FV Leiden, Homozygous: 17×17\times     * FV Leiden (Heterozygous) + OC: 30−35×30-35\times     * FV Leiden (Homozygous) + OC: 100× or more100\times\text{ or more}     * Prothrombin 20210, Heterozygous: 3×3\times     * Prothrombin 20210 (Heterozygous) + OC: 16×16\times

Cystic Fibrosis (CF)

  • Epidemiology: Most common genetic disease in Caucasians.
  • Inheritance: Autosomal recessive.
  • Statistics: Approximately 1 in 2001 \text{ in } 200 individuals are affected; 1 in 251 \text{ in } 25 are carriers.
  • Gene Details: The CFTR gene was identified in 1989 on chromosome 7q7q. It consists of 2727 exons and spans a total of 250 kb250\,kb.
  • Mutational Diversity: Over 13001300 unique mutations have been identified.
  • Most Common Mutation: ΔF508\Delta F508.

Pharmacogenomics and Cytochrome P-450

  • Cytochrome P-450 Polymorphisms: These are drug-metabolizing enzymes. Genetic testing can predict how a patient will respond to or the effectiveness of certain pharmaceutical drugs. These polymorphisms can either inhibit or induce drug metabolism.
  • Pharmacogenomics definition: The study of genetic variations in drug response using genomic data across many samples to provide a personalized medicine approach.

Complexities in Disease Expression

  • Penetrance: The frequency with which a disease phenotype is expressed in individuals carrying the mutation.
  • Incomplete Penetrance: A state where the mutation is present, but the individual displays no abnormal phenotype.
  • Variable Expressivity: A situation where the same genetic mutation results in a varied range of phenotypic severity or characteristics.
  • Genetic Heterogeneity: Different independent mutations leading to the same clinical phenotype. This is common in diseases with multiple genetic components.

Non-Mendelian Transmission Patterns

  • Gonadal Mosaicism: A somatic mutation occurring within germ-line cells, meaning the mutation is present in gametes but not necessarily the parent's somatic tissue.
  • Genomic Imprinting: Nucleotide or histone modifications (such as methylation of Cytosine residues) that silence a gene without changing the DNA sequence. This process occurs during egg or sperm production.     * Uniparental Disomy/Deletion Effects: The phenotype depends on whether the maternal or paternal allele is lost.     * Prader-Willi Syndrome: Caused by a regional deletion or mutation on the paternally inherited chromosome 1515.     * Angelman Syndrome: Caused by a regional deletion or mutation on the maternally inherited chromosome 1515.
  • Nucleotide Repeat Expansion: The disruption of gene function caused by an increase in allele size due to repeated triplet sequences.
  • Mitochondrial Inheritance: Maternal inheritance of genes located within the mitochondria.     * Homoplasmy: A state where all mitochondria in a cell are identical (either all normal or all mutant).     * Heteroplasmy: A mix of normal and mutant mitochondria within a single cell. Disease severity depends on the ratio of mutant to normal mitochondria.

Genetic Testing Limitations and Ethical Concerns

  • Methodological Gaps: Molecular analysis may miss intergenic mutations in splice sites or regulatory regions if only coding regions (exons) are sequenced.
  • Focus on Phenotype: Therapeutic targets are often phenotypic rather than genetic.
  • Ethics: Nonsymptomatic diagnosis (testing before symptoms appear) raises significant ethical questions regarding privacy and psychological impact.
  • Multifactorial Nature: Most traits and diseases are multifactorial, making genetic-only analysis incomplete.

Summary Table: Single-Gene Disorders and Molecular Methods

DiseaseType of ProteinGene (Location)Mutation TypeMolecular Methods
Sickle Cell AnemiaStructural (Hemoglobinopathy)Hemoglobin beta (11p15.511p15.5)MissenseSequencing, PCR-RFLP
Marfan SyndromeStructural (Connective tissue)Fibrillin (15q21.115q21.1)MissenseSequencing, Linkage analysis
Muscular DystrophyMembrane-associatedDystrophin, DMD (Xp12.2Xp12.2)DeletionSouthern blot RFLP, 2121 multiplex PCR, linkage
Familial HypercholesteremiaCell surface receptorLDL receptor (19p13.219p13.2)Deletions, point mutationsProbe amplification, sequencing
Vitamin D-resistant RicketsNutritional/ReceptorVitamin D receptor (12q12−q1412q12-q14)Point mutationsSouthern blot RFLP, sequencing
Neurofibromatosis type 1Cell growth regulatorNeurofibromin (17q11.217q11.2)Missense, frameshift, splice siteSequencing, linkage analysis
Neurofibromatosis type 2Cell growth regulatorMerlin, NF-2 (22q1222q12)Nonsense, frameshift, splice siteLinkage analysis
Li-Fraumeni syndrome (LFS)Cancer predispositionTP53 (17p1317p13)MissenseSequencing, SSCP, DGGE
Alkaptonuria (Ochronosis)Enzyme (Metabolic)Homogentisic acid oxidase (3q21−q233q21-q23)Missense, frameshift, splice sitecDNA sequencing, SSCP
Phenylketonuria (PKU)Enzyme (Metabolic)PAH (12q24.112q24.1)Splice site, missense, deletionsLigase chain reaction, direct sequencing
SCIDImmunodeficiencyAdenosine deaminase (20q13.1120q13.11)Point mutationsDirect sequencing, capillary electrophoresis

Note on LFS: A significant proportion of Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like (LFL) kindred do not have demonstrable TP53 mutations.